

What is claimed is:

1. Use of an antibody or antigen-binding fragment thereof that binds specifically to complement factor 5 (C5) protein, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an HCDR1, HCDR2 and HCDR3 of a heavy chain variable region that comprises an amino acid sequence of SEQ ID NO: 98, and a light chain variable region comprising an LCDR1, LCDR2 and LCDR3 of a light chain variable region that comprises an amino acid sequence of SEQ ID NO: 106, in the manufacture of a medicament for ~~preventing~~, treating or ameliorating a disease or disorder associated with C5₂,

wherein the disease or disorder is selected from atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration, geographic atrophy, uveitis, neuromyelitis optica, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, a disorder of inappropriate or undesirable complement activation, a hemodialysis complication, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, an inflammatory disorder, inflammation of an autoimmune disease, Crohn's disease, adult respiratory distress syndrome, thermal injury, a burn, frostbite, a post-ischemic reperfusion condition, myocardial infarction, capillary leak syndrome, obesity, diabetes, Alzheimer's disease, schizophrenia, epilepsy, atherosclerosis, vasculitis, bullous pemphigoid, C3 glomerulopathy, membranoproliferative glomerulonephritis, diabetic nephropathy, Alport's syndrome, progressive kidney failure, a proteinuric kidney disease, renal ischemia-reperfusion injury, lupus nephritis, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease, sepsis, an immune complex disorder, an autoimmune disease, a renal disorder, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, hemolytic anemia, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolism, pulmonary infarct, pneumonia, and myasthenia gravis.

2. The use according to claim 1, wherein the antibody or antigen-binding fragment comprises:

a heavy chain variable region that comprises an HCDR1 that comprises an amino acid sequence of SEQ ID NO: 100, an HCDR2 that comprises an amino acid sequence of SEQ ID NO: 102, and an HCDR3 that comprises an amino acid sequence of SEQ ID NO: 104; and

a light chain variable region that comprises an LCDR1 that comprises an amino acid sequence of SEQ ID NO: 108, an LCDR2 that comprises an amino acid sequence of SEQ ID NO: 110, and an LCDR3 that comprises an amino acid sequence of SEQ ID NO: 112.

3. The use according to claim 1 wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that comprises an amino acid sequence of SEQ ID NO: 98.

4. The use according to claim 1 wherein the antibody or antigen-binding fragment comprises a light chain variable region that comprises an amino acid sequence of SEQ ID NO: 106.

5. The use according to claim 1 wherein the antibody or antigen-binding fragment comprises a heavy chain variable region that comprises an amino acid sequence of SEQ ID NO: 98, and a light chain variable region that comprises an amino acid sequence of SEQ ID NO: 106.

6. The use according to claim 5, wherein the antibody or antigen-binding fragment is a full antibody molecule.

7. The use according to claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain that comprises an amino acid sequence of SEQ ID NO: 353.

8. The use according to claim 1, wherein the antibody or antigen-binding fragment comprises a light chain that comprises an amino acid sequence of SEQ ID NO: 354.

9. The use according to claim 1, wherein the antibody or antigen-binding fragment is a full antibody molecule that comprises a heavy chain that comprises an amino acid sequence of SEQ ID NO: 353; and a light chain that comprises an amino acid sequence of SEQ ID NO: 354.

~~10. The use according to any one of claims 1-9, wherein the disease or disorder is selected from the group consisting of atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal~~

~~hemoglobinuria (PNH), age-related macular degeneration, geographic atrophy, uveitis, neuromyelitis optica, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, a disorder of inappropriate or undesirable complement activation, a hemodialysis complication, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, an inflammatory disorder, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, thermal injury, a burn, frostbite, post-ischemic reperfusion conditions, myocardial infarction, capillary leak syndrome, obesity, diabetes, Alzheimer's disease, schizophrenia, epilepsy, atherosclerosis, vasculitis, bullous pemphigoid, C3 glomerulopathy, membranoproliferative glomerulonephritis, diabetic nephropathy, Alport's syndrome, progressive kidney failure, a proteinuric kidney disease, renal ischemia-reperfusion injury, lupus nephritis, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease, sepsis, an immune complex disorder, an autoimmune disease, a renal disorder, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, hemolytic anemia, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolism, pulmonary infarct, pneumonia, and myasthenia gravis.~~

~~11. The use according to any one of claims 1-9, for preventing a disease or disorder associated with C5.~~

~~12.10. The use according to any one of claims 1-9, wherein the antibody or antigen-binding fragment thereof is to be administered in combination with a second therapeutic agent.~~

~~13.11. The use according to claim 12.10, wherein the second therapeutic agent is selected from the group consisting of an anti-coagulant, an anti-inflammatory drug, an antihypertensive, an immunosuppressive agent, a lipid-lowering agent, an anti-CD20 agent, rituximab, an anti-TNF agent, infliximab, an anti-seizure agent, a C3 inhibitor, a second anti-C5 antibody, and an anti-thrombotic agent.~~

~~14.12. The use according to any one of claims 1-9, wherein the antibody or antigen-binding fragment thereof is to be administered subcutaneously or intravenously.~~

~~45.~~13. The use according to claim 9, wherein the disease or disorder is paroxysmal nocturnal hemoglobinuria (PNH).

~~46.~~14. The use according to claim 9, wherein the disease or disorder is myasthenia gravis.

~~47.~~15. The use according to claim 9, wherein the disease or disorder is age-related macular degeneration, uveitis or geographic atrophy.

~~48.~~16. The use according to claim 9, wherein the disease or disorder is atypical hemolytic uremic syndrome (aHUS).

~~49.~~17. The use according to claim 9, wherein the disease or disorder is neuromyelitis optica.